**Benha Journal of Applied Sciences (BJAS)** **print: ISSN 2356–9751**
**Vol.(5) Issue(4) Part (2) (2020), (193-201)** **online: ISSN 2356–976x**
**http://bjas.journals.ekb.eg**

# Myocardial Injury in Metabolic Acidosis of Non- Dialysis Dependent Ckd Patients.

T.S.Rashaad, S.H.Abdel Aziz, A.T.Mahmoud, H.G.Abdel Salam and E.L.El-Shahawy
Internal Medicine and Nephrology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
E-Mail:ahmed2356@gmail.com

**Abstract**

Amendment of metabolic acidosis (MA) by utilizing oral sodium bicarbonate treatment (OSBT) in non-dialysis subordinate constant kidney malady (CKD) patients with MA positively affects myocardium as it improves the useful boundaries and postpone exacerbating of the auxiliary boundaries through change of hazard factors as remedy of MA prompts increment of eGFR, abatement of uremia, diminishing of serum uric corrosive level, better control of DM, improvement of lipid profile, thyroid profile and lack of healthy sustenance irritation complex disorder (MICS). To survey the relationship between myocardial injury and MA in non-dialysis subordinate CKD patients and the effect of the adjustment of MA on myocardium. The examination was done at nephrology unit, inside medication division, at Banha University Hospitals on a half year's term, where 50 patients were chosen. Echocardiography, blood vessel blood gases, anion hole, e GFR, serum uric corrosive, lipid profile, pee investigation, troponin I, CK-MB, serum creatinine, HA1C, serum egg whites and CRP were estimated when OSBT. Mean blood PH measurably noteworthy expanded from 7.26±0.03 to 7.35±0.003 (p esteem < 0.001). Mean serum $HCO3^{-}$ measurably noteworthy expanded from 13.65±1.19 to 23.56±0.74 (p esteem < 0.001). Mean LVESD factually noteworthy diminished from 3.86±0.47 to 3.78±0.54 cm (p esteem 0.035). Mean LVESD no factually critical contrast from 5.62±0.43 to 5.63±0.42 (p esteem 0.76). Mean EF% measurably critical expanded from 52 to 57 % (p esteem < 0.001). OSBT positively affects myocardium by progress of the useful boundaries and defer intensifying of the basic boundaries.

**Keywords:** MA, CKD, OSBT, Echocardiography changes. (OSBT) Oral sodium bicarbonate therapy, (CKD) Chronic Kidney Disease, (MA) Metabolic Acidosis.

## 1. Introduction

Interminable kidney illness (CKD) is characterized as anomalies of kidney structure or capacity, present for >3 months, with suggestions for wellbeing [1].

CKD is one of the most widely recognized illnesses around the world. It is expanding in frequency and predominance [2].

Cardiovascular illness (CVD) is the main source of bleakness and mortality in CKD patients, happening even at the most punctual phases of CKD without show vascular malady. An evaluated increment in CVD chance happens with declining renal capacity [3].

CKD is related with expanded pervasiveness of accompanying CHF, ischemic coronary illness, cardiovascular arrhythmias (most usually atrial fibrillation), and valvular calcification [4].

As indicated by the U.S. Renal Data System report distributed in 2013, and 43% of patients with CKD and CVD had cardiovascular breakdown (HF), 15% had a past filled with intense myocardial dead tissue (AMI), the proportionate extents in non-CKD patients with CVD were 18.5% and 6.4% individually [5].

Metabolic acidosis generally characterized as a decrease in serum bicarbonate (HCO3-) fixation frequently connected with a decrease in blood PH, is a typical backup of dynamic ceaseless kidney malady [6].

Observational investigations have indicated that metabolic acidosis by and large creates when the GFR falls under 25 ml/min/1.73 m2. Be that as it may, it can show up prior over the span of CKD especially if extra deformities in rounded corrosive discharge are available as, when hyporeninemic hypoaldosteronism or anatomical harm to the gathering pipe is available [7].

The hypobicarbonatemia is typically gentle to direct in degree, with serum [HCO3] fluctuating somewhere in the range of 12 and 23 mEq/l, the blood pH >7.2, and the anion hole variable. Serious metabolic acidosis without a considerable increment in endogenous net corrosive creation or bicarbonate misfortunes is bizarre [8].

In patients with moderate and progressed CKD, the relationship between serum bicarbonate fixation and all-cause mortality is U-formed. The least death rate is found in patients with serum bicarbonate convergence of 26-29 mEq/l. The most noteworthy death rate is seen among patients with serum bicarbonate levels of < 22 mEq/l however an expansion in mortality is additionally found in patient's serum bicarbonate levels>29 mEq/l [9].

Metabolic acidosis may have different antagonistic impacts in patients with CKD, including adjusted skeletal digestion [10], insulin opposition [11] and quickened movement of kidney sickness [12].

Acidosis has been related with the decrease of Na + - k-ATPase action in myocardial cells which could prompt diminished myocardial contractility and congestive cardiovascular breakdown. Moreover, acidosis controls endothelial cell attachment and may assume a job in the inflammatory reaction of vascular endothelial cells [13].

Constant inflammation regularly found in patients with CKD may incline to an expanded pace of atherosclerosis. Acidosis is related with expanded endothelin and aldosterone levels. A high aldosterone level was demonstrated to be identified with expanded cardiovascular malady chance. It is sensible to theorize that the metabolic acidosis brings about increment inflammation, atherosclerosis, and raised endothelin and aldosterone levels could contribute t o an adjustment in left ventricular geometry [14].

Thirty days of oral sodium bicarbonate treatment in patients with somewhat decreased eGFR diminished plasma endothelin-1 and aldosterone levels without an adjustment in blood corrosive base boundaries [15].

Hypothetically, soluble base treatment could exacerbate vascular calcification, however no examination has been acted in people to test this impact [16].

Nonetheless, treatment with sodium bicarbonate might be related with some reactions, for example, hypokalemia, ionized hypocalcaemia, hypercapnia, prolongation of the QTc stretch, an ascent in the urinary discharge of sodium, and the possibility to disintegrate vascular calcifications on constant organization [17].

Oral sodium bicarbonate supplementation to accomplish pre-dialysis serum bicarbonate levels of 24 mEq/L diminished movement of auxiliary hyperparathyroidism in patients with high bone turnover and invigorated bone turnover in patients with low bone arrangement. Treatment of acidosis may likewise expand the affectability of the parathyroid organs to calcium PTH declined in the year after antacid treatment was started [18].

Rewarding acidosis enhances the insulin flagging deformity and diminishes muscle breakdown [19].

Bicarbonate supplementation eased back the pace of GFR misfortune and diminished the movement to end-stage renal illness requiring dialysis [20].

Diet high in creature protein, has an enormous dietary corrosive burden. Alternately, an eating routine wealthy in foods grown from the ground contains more prominent amounts of base antecedents. Expanded foods grown from the ground utilization raised serum bicarbonate level [21].

## 2. Patient and methods

This prospectively study was carried out at nephrology unit, internal medicine department, at Banha University Hospitals on 6 months' duration, where 50 patients were selected. After approval of the local Ethics Committee and obtaining written informed consents.

**Inclusion criteria included**

Male and female patients**,** age > 18 years, patients who are non- dialysis dependent chronic kidney disease, patients with CKD with MA **Exclusion criteria included** age < 18 years, patients with chronic kidney disease on hemodialysis and pregnancy

**Methods**

For each patient was admitted to nephrology unit who is non- dialysis dependent chronic kidney disease patient with metabolic acidosis Patients were received oral sodium bicarbonate 650 mg tablet (twice to three times per day) till $HCO_3^-$ > 22 mEq/L& the following was done:

**1-History**: Age, Sex, Cardiovascular history.

**2-Clinical examination**: blood pressure was measured by sphygmomanometer, Measurement were obtained before during and after OSBT, Cardiovascular examination if there was a lower limb edema

**3-Radiological study:** Echocardiography: It was used in determining cardiac function (ejection fraction, LVESD and LVEDD), cardiac dimensions (LV dimension).

**4-Laboratory assessment** Before & after OSBT we measured arterial blood gases, serum sodium, serum potassium, serum chloride, anion gap= $(Na^+ + K^+) - (HCO3^- + Cl^-)$, e GFR measured using modification diet in renal disease (MDRD) study equation, serum calcium, serum phosphorus, PTH, serum uric acid, lipid profile (total cholesterol, HDL, LDL and triglyceride), urine analysis (specific gravity, PH), 24h urinary albumin ,troponin I, CK-MB, fasting &2h post prandial blood sugar, blood urea, serum creatinine, HA1C, serum albumin, CRP.

***5*-ECG**

### 2.1 Statistical methodology

**Data management**

The clinical data were recorded on a report form. These data were tabulated and analysed using the computer program SPSS (Statistical package for social science) version 20 to obtain:

**Descriptive data**

Descriptive statistics were calculated for the data in the form of:

1- Mean and standard deviation $(\pm SD)$. Median and inter-quartile range (IQR) for quantitative data.

2- Frequency and distribution for qualitative data.

**Analytical statistics**

In the statistical comparison between the different groups, the significance of difference was tested using one of the following tests: -

1- test: - Used to compare mean of two groups of quantitative data of parametric and non-parametric respectively.

2- Paired t test and willcoxon test: Used to compare mean of variables in different time periods of quantitative data of parametric and non-parametric respectively.

3- Student's *t*-test and Mann-Whitney 3-Inter-group comparison of categorical data was performed by using chi square test ($X^2$-value) and fisher exact test (FET).

$$x^2 = \frac{\sum (observed - expected)^2}{Expected}$$

$$Expected = \frac{col.total \; x \; row total}{Grand total}$$ Correlation coefficient: - Pearson and spearman correlation

To find relationships between variables parametric and non-parametric respectively.

A *P* value <0.05 was considered statistically significant while >0.05 statistically insignificant P value <0.01 was considered highly significant in all analyses.

## 3. Results

A total of 50 CKD patients, stage 3B-5 with MA were enrolled in the study including 58% (n=29) females and 42% (n=21) males. The median age was 54±10 years; average estimated glomerular filtration rate (eGFR) using modification diet in renal disease (MDRD) was 25.06±6.05 ml/min/1.73m$^2$ table (1).

The cause of CKD was DM &hypertension 40% (n=20), DM12% (n =6), hypertension 8% (n=4), glomerulonephritis 16% (n=8), APKD 12% (n=6) & recurrent stone former 12% (n=6) were included into final analysis table (2).

blood PH and serum $HCO3^{-}$ levels were statistically significant increased & anion gap was statistically significant decreased after OSBT as p value was (< 0.001, < 0.001 and < 0.001 respectively) table (3).

eGFR was statistically significant increased & serum creatinine & blood urea were statistically significant decreased after OSBT as p value was (< 0.001, < 0.001 and < 0.001 respectively) table (3).

Serum sodium was statistically significant increased & serum potassium & serum chloride were statistically significant decreased after OSBT as p value was (< 0.001, < 0.001 and < 0.001 respectively) table (4).

Serum albumin was statistically significant increased & serum CRP was statistically significant decreased after OSBT as p value was (< 0.001 and < 0.001 respectively) table (4).

High sensitive troponin I & CK-MB levels were statistically significant decreased after OSBT as p value was (< 0.001 and < 0.001 respectively) table (4).

□ Serum Ca, serum P, PTH & serum uric acid levels were statistically significant decreased after OSBT as p value was (< 0.001, 0.006, < 0.001 and < 0.001 respectively) table (5).

FBS, 2HPP & HA1c were statistically significant decreased after OSBT as p value was (< 0.001, < 0.001 and < 0.001 respectively) table (5).

Triglyceride, total cholesterol, HDL-C & LDL-C were statistically significant decreased after OSBT as p value was (< 0.001, < 0.001, 0.001 and < 0.001 respectively) table (5).

Thyroid dysfunction was considered if patient's thyroid hormones fall outside the reference range; free T3 (3.0–6.8 pmol/L), free T4 (10.0–25.0 pmol/L) and TSH (0.25– 5 mIU/L). Euthyroid was considered if thyroid hormone levels fall within reference range. Overt hypothyroidism was defined as TSH > 5 mIU/L and free T3 < 3.0 pmol/L and free T4 < 10.0 pmol/L. Subclinical hypothyroidism was considered if TSH > 5 mIU/L and free T3 and free T4 within reference range. Subclinical hyperthyroidism was defined as TSH < 0.25 mIU/L and free T3 and freeT4 within reference range. Sick euothyroid syndrome was considered if free T3 < 3.0 pmol/L and free T4 within reference range or < 10.0 pmol/L and TSH < 0.25 mIU/L or within reference range.

Thyroid dysfunction was found in 64% (n=32), the most common thyroid dysfunction is being subclinical hypothyroidism in 30% (n=15) followed by sick euothyroid syndrome in 16% (n=8), followed by overt hypothyroidism in 14% (n=7), followed by subclinical hyperthyroidism in 4%(n=2).

After alkali therapy, total patients that had achieved complete improvement were 56% (n=18). Total patients that had achieved partial improvement were 34.5% (n=11). Total patients that had achieved no improvement were 9.4% (n=3) table (6).

FT3 & FT4 levels were statistically significant increased & serum TSH was statistically significant decreased after OSBT as p value was (< 0.001, < 0.001 and < 0.002 respectively) table (7).

24h urinary albumin was statistically significant decreased after OSBT as p value < 0.001 table (7).

Specific gravity of urine was statistically significant increased & PH of urine was statistically significant decreased after OSBT as p value was (< 0.001and < 0.001 respectively) table (7).

There were no statistically significant difference in QT-C (ms), ST segment depression & t wave inversion before and after OSBT as p value was (0.052 and 1.0 respectively) table (7).

There were no statistically significant difference in LA, IVS and PW between the studied group before and after OSBT as p value was (0.63, 0.83 and 0.35 respectively) table (8).

EF% was statistically significant increased &LVESD was statistically significant decreased after OSBT as p value was (< 0.001 and 0.035 respectively) & there was no significant difference in LVEDD between the before and after OSBT as p value was 0.76 table (8).

**Table (1)** The mean of the age and eGFR and sex in the studied group.

| | **The studied group (50)** |
|---|---|
| **Age /year mean ±SD (range)** | 54.06±10 (32-70) |
| **Sex no (%)** | |
| **Male** | 21 (42.0) |
| **Female** | 29 (58.0) |
| **EGFR** | 25.06±6.05 |
| **ml/min/1.73m2 mean ±SD (range)** | |

**Table (2)** CKD causes in the studied group.

| | **N (%)** |
|---|---|
| **CKD Causes** | |
| **APKD** | 6(12.0) |
| **DM** | 6(12.0) |
| **HTN** | 4(8.0) |
| **DM&HTN** | 20(40.0) |
| **GN** | 8(16.0) |
| **Recurrent stone former** | 6(12.0) |

**Table (3)** Comparison between pre-treatment and post-treatment in the treatment group according to PH, $HCO3^{-}$, anion gap anion gap, e GFR, serum creatinine and blood urea.

| | | Pre-treatment | Post-treatment | P value |
|---|---|---|---|---|
| **PH** | Mean ± SD | 7.26±0.03 | 7.35±0.003 | <0.001 |
| **$HCO_3$(Meq/l)** | Mean ± SD | 13.65±1.19 | 23.56±0.74 | <0.001 |
| **Anion gap (mmol/l)** | Mean ± SD | 19.67±2.02 | 13.25±1.10 | <0.001 |
| **e GFRml/min/1.37 $m^2$** | Mean ± SD | 25.06±6.05 | 26.44±7.65 | <0.001 |
| **Serum creatinine (mg/dl)** | Mean ± SD | 2.47±0.56 | 2.39±0.65 | <0.001 |
| **Blood urea(mg/dl)** | Mean ± SD | 127.14±19.02 | 122.72±20.98 | <0.001 |

**Table (4)** Comparison between pre-treatment before and post-treatment in the treatment group according to serum Na, serum K and serum Cl, CRP, serum albumin, high sensitive troponin I and CK-MB.

| | | Pre-treatment | Post-treatment | P value |
|---|---|---|---|---|
| **Serum Na (Meq/l)** | Mean ± SD | 136.46±1.75 | 137.5±1.74 | <0.001 |
| **Serum K (Meq/l)** | Mean ± SD | 4.59±0.35 | 4.33±0.38 | <0.001 |
| **Serum Cl (Meq/l)** | Mean ± SD | 108.11±1.94 | 105.1±1.28 | <0.001 |
| **CRP(mg/dl)** | Mean ± SD | 26.96±7.75 | 19.56±7.94 | <0.001 |
| **Serum albumin (g/dl)** | Mean ± SD | 3.72±0.19 | 3.86±0.19 | <0.001 |
| **High sensitive troponin (ng/l)** | Mean ±SD | 30.33±9.19 | 22.21±10.34 | <0.001 |
| **CK-MB (ng/ml)** | Mean ± SD | 21.27±9.85 | 18.3±7.91 | <0.001 |

**Table (5)** Comparison between pre-treatment and post-treatment in the treatment group according to serum total Ca, serum P, PTH, serum uric acid FBG, 2HPP, HA1c, TG, total cholesterol, HDL-C and LDL-C**.**

| | | pre-treatment | post-treatment | P value |
|---|---|---|---|---|
| **Serum total Ca (mg/dl)** | Mean ± SD | 8.34±0.41 | 8.46±0.38 | <0.001 |
| **Serum P(mg/dl)** | Mean ± SD | 4.53±0.46 | 4.46±0.43 | 0.006 |
| **PTH(pg/dl)** | Mean ± SD | 457.98±176.6 | 436.98±175.78 | <0.001 |
| **Serum uric acid (mg/dl)** | Mean ± SD | 8.9±0.57 | 8.16±0.49 | <0.001 |
| **TG (mg/dl)** | Mean ± SD | 198.68±24.16 | 189.68±28 | <0.001 |
| **Total cholesterol (mg/dl)** | Mean ± SD | 247.58±17.4 | 237.4±20 | <0.001 |
| **HDL-C (mg/dl)** | Mean ± SD | 41.82±2.14 | 43.52±2.32 | <0.001 |
| **LDL-C (mg/dl)** | Mean ± SD | 170.1±12.27 | 162.76±11.36 | <0.001 |

**Table (6)** Thyroid profile in the studied group.

| | | n (%) |
|---|---|---|
| **Thyroid profile** | **Euthyroid** | 18(36.0) |
| | **Subclinical hypothyroidism** | 15(30.0) |
| | **Sick euthyroid** | 8(16.0) |
| | **Overt hypothyroidism** | 7(14.0) |
| | **Subclinical hyperthyroidism** | 2(4.0) |
| **Improvement*** | **No improvement** | 3(9.4) |
| | **Complete improvement** | 18(56.2) |
| | **Partial improvement** | 11(34.3) |

**Table (7)** Comparison between pre-treatment and post-treatment in treatment group according to TSH, FT3, FT4, 24hour urinary albumin, QT-C, ST segment depression & t wave inversion**.**

| | | pre-treatment | post-treatment | P value |
|---|---|---|---|---|
| **TSH (UIU/ml)** | Mean ± SD | 5.09±2.78 | 4.59±2.6 | 0.002 |
| **FT3 (pmol/l)** | Mean ± SD | 3.32±0.80 | 3.7±0.73 | <0.001 |
| **FT4 (pmol/l)** | Mean ± SD | 11.95±3.05 | 13.26±2.79 | <0.001 |
| **24h urinary albumin (mg/l)** | Mean ± SD | 655.12±558.62 | 565.62±535.09 | <0.001 |

| Table (7) Continue | | | | |
|---|---|---|---|---|
| **Specific gravity of urine** | Mean ± SD | 1016.88±2.38 | 1020.88±2.37 | <0.001 |
| **PH of urine** | Mean ± SD | 5.5±0.36 | 6.46±0.26 | <0.001 |
| **QT-C** | Mean ± SD | 429.22±30.21 | 423.42±32.34 | 0.052 |
| **ST segment depression & t wave inversion** | | 25(50.0) | 25(50.0) | 1.0 |

**Table (8)** Comparison between pre-treatment and post-treatment in the treatment group according to LA, IVS, PW LVESD, LVEDD and EF%.

| | | Pre-treatment | Post-treatment | P value |
|---|---|---|---|---|
| **LA/cm** | Mean ± SD | 3.66±0.24 | 3.65±0.26 | 0.63 |
| **IVS/cm** | Mean ± SD | 1.16±0.12 | 1.16±0.10 | 0.83 |
| **PW/cm** | Mean ± SD | 1.04±0.13 | 1.05±0.11 | 0.35 |
| **LVESD/cm** | Mean ± SD | 3.86±0.47 | 3.78±0.54 | 0.035 |
| **LVEDD/cm** | Mean ± SD | 5.62±0.43 | 5.63±0.42 | 0.76 |
| **EF%** | Mean ± SD | 52.7±5.7 | 56.02±6.7 | <0.001 |

## 4. Discussion

Cardiovascular sickness (CVD) is the main source of grimness and mortality in CKD patients, happening even at the most punctual phases of CKD without show vascular malady. A reviewed increment in CVD chance happens with compounding renal capacity [3].

Acidosis has been related with the decrease of Na + -k-ATPase action in myocardial cells which could prompt diminished myocardial contractility and congestive cardiovascular breakdown. What's more, acidosis directs endothelial cell bond and may assume a job in the inflammatory reaction of vascular endothelial cells [13].

CKD is related with expanded predominance of associative CHF, ischemic coronary illness, cardiovascular arrhythmias (most normally atrial fibrillation), and valvular calcification [4].

Treatment of CKD tolerant with calcium supplementation, calcitriol, insulin &uric corrosive bringing down medications stayed unmodified, however antihypertensive medication was expanded in 16 patients as there was increment of systolic circulatory strain by 15 - 25 mmHg from pretreatment esteems and 5 – 10 mmHg increment of diastolic pulse from pretreatment esteems while the staying of patients encountered no portion change.

Mellow lower appendage edema showed up at beginning of treatment in 13 patients and little portion of diuretics required for about fourteen days, however no longer requirement for diuretics as lower appendage edema dies down in follow up period.

There was factually critical increment in blood PH, HCO3 and abatement anion hole in treatment bunch after sodium bicarbonate treatment and this is concordant with [28] as they presumed that three months of oral bicarbonate treatment with bicarbonate levels at 22–26 mEq/L was related with huge amendment of MA with increment in blood pH and serum bicarbonate levels. So rectification of MA prompts increment in PH and HCO3 decline anion hole in treatment bunch OSBT.

There was factually critical increment in eGFR and lessening of serum creatinine and blood urea in treatment bunch after sodium bicarbonate treatment this is concordant with de [20] as they reasoned that bicarbonate treatment was a fundamentally lower decrease in creatinine freedom in the treatment gathering [9] summoned the job of endothelin in CKD with MA which assumes a job in renal fermentation through the enactment of ET-B receptors, however which can likewise all the while initiate ET-A receptors with resultant tubulointerstitial injury [9,14], reasoned that endothelin-1 and aldosterone were decreased following 30 days of bicarbonate treatment in stage 2 CKD (GFR 60-90ml/min) with macroalbuminuria [14]. So amendment of MA prompts abatement of endothelin-1 and aldosterone that prompts decline renal injury, increment in eGFR and diminishing in serum creatinine and blood in treatment bunch after OSBT.

There was measurably huge abatement in serum potassium and serum chloride in treatment bunch after sodium bicarbonate treatment. This is concordant with [29] as they inferred that NaHCO3 treatment can diminish serum chloride additionally lessen serum potassium. There was measurably huge increment in serum sodium in treatment bunch after sodium bicarbonate treatment. Our clarification is as with respect to a run of the mill every day portion of NaHCO3 used to treat MA in CKD (2–3 g) is 0.54–0.81 g of sodium [22]. So rectification of MA lead to increment in serum sodium in treatment bunch after OSBT.

There was factually huge increment in serum egg whites in treatment bunch after sodium bicarbonate treatment and this is concordant with de [20] who presumed that following 1 year of bicarbonate treatment serum egg whites levels rose in the treatment gathering.

There was measurably critical lessening in high touchy troponin and CK-MB in treatment bunch after sodium bicarbonate treatment. As the MA brings about expanded aggravation, atherosclerosis, and raised angiotensin II, endothelin and aldosterone levels that could add to an adjustment in left ventricular geometry and demonstrated to be identified with expanded cardiovascular ailment chance [24]. Mama of CKD prompts improved creation of catecholamine, endothelin-1, and aldosterone; which can add to changes in left ventricular mass and geometry [25] Observational

examinations demonstrated that low serum $HCO3^{-}$ is related with expanded rate of hypertension which is a significant supporter of cardiovascular illness [15]. Thyroid brokenness and dyslipidemia in CKD may additionally expand CVD chance prompting expanded bleakness and mortality [16]. Dyslipidemia with higher LDL and lower HDL cholesterol is related with atherosclerotic vascular infection that expansion the danger of CVD occasions [17]. Proteinuria related with movement of renal infection, expand hazard for cardiovascular occasions as myocardial ischemia as it expanded hazard for atherosclerotic occasions and increment cardiovascular mortality [17]). Microalbuminuria may possibly be related with constant aggravation [18]. CRP, as a marker of aggravation, intercedes a few key procedures in the pathogenesis of atherosclerosis [19]. Raised uric corrosive reason renal infection by initiating glomerular harm and rounded ischemia through glomerular hypertension and cortical vasoconstriction. What's more, uric corrosive animates incendiary middle people in vascular cells, including C-responsive protein and monocyte chemoattractant protein and vasoconstrictive factors, for example, thromboxane [20]. Hyperuricemia is unequivocally connected with endothelial brokenness and bringing down uric corrosive improves endothelial brokenness especially in an assortment of conditions. Likewise, hyperuricemia is free hazard factor for hypertension [21]. Wesson et al 2011, presumed that endothelin-1 and aldosterone were decreased following 30 days of bicarbonate treatment in stage 2 CKD (GFR 60-90ml/min) with macroalbuminuria [22]. Ori et al inferred that there was a helpful impact of soluble base treatment on irritation where IL-10 emission from mononuclear cells diminished following multi month of NaHCO3 supplementation in predialysis CKD stage 4 and 5 patients [23]. Besides, adjustment of MA in patients with CKD causes T3 levels to ascend towards ordinary (25). Additionally, [26], reasoned that in a gathering of CKD stage 2–4 patients, the utilization of oral NaHCO3 supplementation for the remedy of MA was related with a lessening in serum levels of LDL (– ), a negligibly oxidized LDL. These discoveries establish proof for a useful impact of salt treatment to forestall LDL oxidation, which has significant ramifications for atherogenesis in CKD patients [26]. In our investigation there was diminishing of LDL-C, serum uric corrosive, CRP and improvement in thyroid capacity (increment of FT3 and FT4) so as a result there was decline in endothelial brokenness, irritation and atherosclerosis. so rectification of MA prompts change of this factors add to diminish of myocardial injury in treatment bunch after OSBT.

There was measurably huge lessening in TSH and increment of FT3 and FT4 in treatment bunch after sodium bicarbonate treatment. As, acidosis brings down serum levels of free T3 and T4 [27]. People with uremia have low basal metabolic rates. This could be connected to a limited extent to the related MA influencing thyroid hormone levels, since MA has been seen as related with diminished triiodothyronine [T3) and thyroxine (T4) and raised thyroid-invigorating hormone levels. Besides, amendment of MA in patients with CKD causes T3 levels to ascend towards typical [28]. TNFα and interleukin-1 repress the outflow of type 1 5' deiodinase, the catalyst liable for T4 to T3 transformation in fringe tissues. This would clarify how constant aggravation and vascular harm related to CKD meddle with the ordinary procedure of T3 amalgamation from T4 [29]. Thus, revision of MA prompts decline of aggravation (decline CRP) after treatment, so prompts increment of FT3, FT4 and reduction of TSH (because of diminishing of the input restraint because of increment of FT3, FT4) in treatment bunch after OSBT.

There was measurably noteworthy reduction of triglyceride, absolute cholesterol and LDL-C and increment of HDL-C in treatment bunch after sodium bicarbonate treatment and this isn't concordant with [26]. Our clarification is there was increment of FT3 and FT4 in treatment bunch after sodium bicarbonate treatment. The impacts of thyroid hormones on lipid digestion incorporate improving use of lipid substrates, expanding in the combination and preparation of triglycerides put away in fat tissue, expanding in the convergence of non-esterified unsaturated fats and increment of lipoprotein-lipase action [27]. As, lipoprotein-lipase catabolize triglycerides and transports free cholesterol to HDL. lecithin cholesterol acyltransferase(LCAT) has an essential in switch cholesterol digestion (cholesterol transport from fringe cell to liver). The action of lipoprotein-lipase and LCAT is directed by thyroid hormone [28]. In this way, adjustment of MA prompts improvement in thyroid capacity (increment of FT3 and FT4) therefore it causes improvement in lipid profile (abatement of triglyceride, all out cholesterol and LDL-C and increment of HDL-C) in treatment bunch after OSBT.

Thyroid brokenness was found in 64% (n=32), the most widely recognized thyroid brokenness was subclinical hypothyroidism 30% (n=15) trailed by wiped out euothyroid disorder 16% (n=8), trailed by obvious hypothyroidism in 14% (n=7), trailed by subclinical hyperthyroidism 4%(n=2).

Our investigation uncovered that patients had accomplished total improvement in treatment bunch after sodium bicarbonate treatment was 56.2% (n=18) was as subclinical hypothyroidism (n=10), wiped out euthyroid (n=8) and patients that had accomplished fractional improvement was 34.5% (n=11) were as subclinical hypothyroidism (n=5), unmistakable hypothyroidism (n=4) and subclinical hyperthyroidism (n=2) and patients that had accomplished no improvement was 9.4% (n=3) was of plain hypothyroidism .

Our examination uncovered that there was measurably huge increment of serum calcium in treatment bunch after sodium bicarbonate treatment and this isn't concordant with (28), as they reasoned that after adjustment of MA in patients with CKD, there was no critical change in complete calcium, phosphorus. Our clarification is as, in CKD with stable MA there is little amounts of calcium were discharged in the pee, yet fecal calcium discharge rose to or surpassed dietary admission. Consistent remedy of MA by NaHCO3 treatment decreased both urinary and fecal calcium discharge and delivered an every day

calcium balance undefined from zero [18)]. Remedy of MA by NaHCO3 treatment brings 1,25(OH)2D3 up in nutrient D insufficient CKD patients [19]. In this way, remedy of MA lead to increment of nutrient D level and diminished both urinary and fecal calcium discharge that lead to increment of all out serum calcium in treatment bunch after OSBT.

There was factually huge lessening of PTH in treatment bunch after sodium bicarbonate treatment and this is concordant with [28], as they inferred that after adjustment of MA in patients with CKD it weakens the ascent in PTH, which may forestall the injurious long haul results of auxiliary hyperparathyroidism. Treatment of MA may likewise expand the affectability of the parathyroid organs to calcium, PTH declined in the year after soluble base treatment was started [18]. Along these lines, adjustment of MA lead to increment of all out calcium likewise increment the affectability of the parathyroid organs to calcium prompting lessening of PTH in treatment bunch after OSBT.

There was factually critical lessening serum phosphorous in treatment bunch after sodium bicarbonate treatment. As, kidney infection progress, there is lessened filtration and discharge of phosphate coming about in hyperphosphatemia [19]. As in this gathering after sodium bicarbonate treatment there was increment of eGFR that prompts increment of urinary discharge of phosphorous.

There was measurably noteworthy reduction in serum uric corrosive level in treatment bunch after sodium bicarbonate treatment and this isn't concordant with from Rizzetto F et al 2017 as they reasoned that following 1 year of oral NaHCO3 supplementation to arrive at serum $HCO3^{-}$levels > 22 M demonstrated that there were no huge contrasts in the progressions of serum uric corrosive look at pretreatment and post-treatment. Our clarification is in this investigation serum uric corrosive before treatment was not raised (6.6±1.0 mg/dl) however in our examination serum uric corrosive before treatment was (8.9±0.6mg/dl).As, a few hemodynamics and metabolic confusions can influence uric corrosive renal discharge corrosive base irregularity as MA, variety of compelling vascular volume, for example, renin-angiotensin framework adjustment, low urinary PH and insulin opposition can impact urate renal leeway [29], as in our investigation oral bicarbonate treatment improve insulin obstruction (noteworthy lower HA1C, FBG and 2HPP after treatment), reduction of urinary PH and increment of eGFR so every one of these components increment urinary uric corrosive discharge.

There was factually huge reduction in 24-hour urinary egg whites in treatment bunch after sodium bicarbonate treatment and this is concordant with Mahajan et al., 2010 inferred that patients who got sodium bicarbonate experienced altogether less slants of the eGFR, diminishes in urinary markers of cylindrical injury and pee endothelin, and adjustment of albuminuria. aldosterone/mineralocorticoid receptor (MR) is a significant supporter of CKD movement. Aldosterone/MR actuates glomerular podocytes injury, causing the interruption of the glomerular filtration boundary and proteinuria. The components by which aldosterone/MR interceded podocytes injury, including oxidative pressure, endoplasmic reticulum stress [27]. As, MA in CKD prompts increments in ET-1 levels to encourage corrosive disposal add to tubulointerstitial fibrosis (28). proteinuria is related with endothelial brokenness and aggravation [29,28] reasoned that endothelin-1 and aldosterone were diminished following 30 days of bicarbonate treatment in stage 2 CKD (GFR 60-90ml/min) with macroalbuminuria [22]. So amendment of MA prompts decline aggravation (diminishing of CRP) and aldosterone so prompts decline podocytes injury and reduction of albuminuria in treatment bunch after OSBT.

There was factually noteworthy increment in explicit gravity of pee and lessening of PH of pee in treatment bunch after sodium bicarbonate treatment. As, a few hemodynamics and metabolic disturbances can influence uric corrosive renal discharge corrosive base unevenness as MA, variety of compelling vascular volume, for example, renin-angiotensin framework change, low urinary PH and insulin obstruction can impact urate renal freedom [29], as in our investigation oral bicarbonate treatment prompts increment of eGFR and increment uric corrosive discharge in pee that lead to increment of explicit gravity of pee likewise oral bicarbonate treatment decline urinary PH in treatment bunch after OSBT.

There was no factually noteworthy distinction in QT-C span between pre-treatment and post-treatment and this isn't concordant with [28], as they presumed that adjustment of MA improves QT stretch. Our clarification is as this examination included CKD patients whose had ordinary ECG, typical transthoracic echocardiography with typical left ventricular discharge portion with 3 months and electrolytes as calcium, potassium and phosphorus inside typical range, yet in our investigation there were variations from the norm in ECG as ischemic changes, irregularities in transthoracic echocardiography as LVH and anomalies in electrolytes as potassium (hyperkalemia) and phosphorus along these lines, in our examination there were no huge contrasts in QT-C stretch between pre-treatment and post-treatment. there was no factually noteworthy contrast in ST portion sadness &t wave reversal between pre-treatment and post-treatment.

There was no measurably critical in left atrial (LA) distance across or in interventricular septum (IVS) breadth or in back divider (PW) measurement or left ventricular end diastole width (LVEDD) between pre-treatment and post-treatment. there was measurably noteworthy diminishing of left ventricular end systole distance across (LVESD) and increment of left ventricular discharge part (EF%) in treatment bunch after OSBT. Incessant Renal Insufficiency Cohort study reasoned that lower serum bicarbonate in CKD related with progressively expanded in left ventricular hypertrophy, left ventricular mass, left ventricular geometry and diastolic brokenness [28]. Constant MA of CKD decrease of Na+ - K+ ATPase movement in myocardial cells which could prompt diminished myocardial contractility and congestive cardiovascular breakdown (26). Hyperphosphatemia is a hazard factor for cardiovascular infection and mortality

[27]. Ori et al presumed that there was a valuable impact of antacid treatment on aggravation where IL-10 emission from mononuclear cells diminished following multi month of NaHCO3 supplementation in predialysis CKD stage 4 and 5 patients [28]. Likewise, Rizzetto et al, inferred that in a gathering of CKD stage 2–4 patients, the utilization of oral NaHCO3 supplementation for the MA was related with a decline in serum levels of LDL (– ), a negligibly oxidized LDL. These discoveries establish proof for a helpful impact of soluble base treatment to forestall LDL oxidation, which has significant ramifications for atherogenesis in CKD patients [29]. remedy of MA in patients with CKD causes T3 levels to ascend towards typical [30]. Along these lines, revision of MA prompts improvement of eGFR and thyroid capacity and diminishing of LDL, decline serum uric corrosive, decline serum phosphorous lessening CRP, decline albuminuria and abatement heart catalysts. Along these lines, alteration of these hazard factors decline irritation, atherogenesis, endothelial brokenness, myocardial injury, increment of myocardial contractility and forestall further LVH.

**References**


[1] C. Y. Hsu, J. D. Ordonez, G.M. Chertow, Fan. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int, Vol. 74,PP. 101–107,2008.

[2] J.Coresh, E.Selvin, L. A. Stevens, Manzi. Prevalence of chronic kidney disease in the United States. JAMA,Vol. 298,PP.2038–47,2007.

[3] E.Di Angelantonio, R.Chowdhury, N.Sarwar, Aspelund. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study BMJ,Vol. 341,PP.c4986,2010.

[4] S. P. Sedlis, C. T. Jurkovitz, P. M. Hartigan, Goldfarb. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol,Vol. 104,PP.1647–1653,2009.

[5] M. A. Onuigbo. The CKD enigma with misleading statistics and myths about CKD, and conflicting ESRD and death rates in the literature: results of a 2008 U.S population-based cross-sectional CKD outcomes Ren Fail analysis,Vol. 35(3),PP.338–343,2013.

[6] J. A.Kraut, I. Kurtz. Metabolic acidosis of CKD: Diagnosis, clinical characteristics, and treatment. Am J Kidney Dis,vol 45(6),PP.978–993,2005.

[7] M.Schambelan, A.Sebastian, E.G. Biglieri. Prevalence, pathogenesis, and functional significance of aldosterone defciency in hyperkalemic patients with chronic renal insufficiency Kidney Int,Vol. 17(1),PP.89–101,1980.

[8] R.M.Hakim, J.M.Lazarus. Biochemical parameters in chronic renal failure. Am J Kidney Dis,Vol. 11(3),PP.238–247,1988.

[9] C.P. Kovesdy, J.E. Anderson, K.Kalantar-Zadeh. "Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD," Nephrology Dialysis Transplantation,Vol.24 (4),PP.1232–1237,2009.

[10] J.A.Kraut. Disturbances of acid–base balance and bone disease in end-stage renal disease. Sem Dial,Vol.13(4),PP.261–266,2000.

[11] R.H.Mak. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney international,Vol.54(2),PP.603–607,1998.

[12] J.L.Bailey, X.Wang, B.K. England. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest,Vol. 97(6),PP.1447–1453,1996.

[13] A.Chen, L.Dong, N.R Leffler, A.S.Asch. Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP/ Epac pathway. PLoS ONE,Vol. 6(11) e27,PP.586,2011.

[14] D.E.Wesson, J.Simoni, K. Broglio, S.Sheather. Acid retention accompanies reduced GFR in humans and increase plasma levels of aldosterone and endothelin. Am J Physiol Renal Physiol,Vol. 300(4),PP. F830-F837,2011.

[15] D.E.Wesson. Does an Acid-Milieu in Chronic Kidney Disease Contribute to Its Increased Cardiovascular Mortality? Am J Nephrol,vol 43(6),PP.408–410,2016.

[16] F.J.Mendoza, I.Lopez, Montes, A.Oca, J.Perez, M.Rodriguez, E.Aguilera-Tejrro. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int. 73(4):407-414,2008.

[17] S.A.Al-Abri, T.Kearney. "Baking soda misuse as a home remedy: case experience of the California Poison Control System," Journal of Clinical Pharmacy and Therapeutics,Vol. 39(1),PP.73–77,2014.

[18] K.A.Graham, N.A.Hoenich, M.Tarbit, M.K.Ward, T.H .Goodship. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. Journal of the American Society of Nephrology: JASN,Vol. 8(4),PP.627–631,1997.

[19] R.H Mak. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney international,Vol.54(2),PP.603–607,1998.

[20] I.De Brito-Ashurst, M.Varagunam, M.J Raftery, M.M.Yaqoob. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol, Vol. 20(9) 2075,PP.2084,2009.

[21] N.Goraya, J.Simoni, C.H.Jo, D.E.Wesson. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin JAm Soc Nephrol. 8(3):371-381,2013.

[22] I.Łoniewski, D.E.WessonBicarbonate therapy for prevention of chronic kidney disease progression. Kidney International,Vol. 85(3),PP.529–535. ,2014.

[23] K.Kalantar-Zadeh, R.Mehrotra, D.Fouque, J.D.Kopple. Metabolic Acidosis and Malnutrition-Inflammation Complex Syndrome in Chronic Renal Failure Seminars in Dialysis,Vol. 17(6),PP.455–465,2004.

[24] M.Dobre, , J.Roy, K.Tao, A.H Androsen, N.Bansal, T.Hostetter. Serum bicarbonate and structural and functional cardiac abnormalities in CKD – a report from the CRIC study. Am J Nephrol,Vol. 43(6),PP.411–420,2016.

[25] A.Bellasi, L.D.iMicco, D.Santoro. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease BMC Nephrology 17(1),158,2016.

[26] F.Rizzetto, D.Mafra, A.B.Barra. One-Year Conservative Care Using Sodium Bicarbonate Supplementation Is Associated with a Decrease in Electronegative LDL in Chronic Kidney Disease Patients: A Pilot Study Cardiorenal Med, Vol. 7(4),PP.334–341,2017.

[27] Z.C.Yenigun, C.Aypak, D.Turgut. effect of MA in QT intervals in patient with chronic kidney disease .int.j artif organs,Vol. 39(6),PP.272-276. ,2016.

[28] R.P.Mathur, S.C.Dash, N.Gupta. Effects of Correction of Metabolic Acidosis on Blood Urea and Bone Metabolism in Patients with Mild to Moderate Chronic Kidney Disease: A Prospective Randomized Single Blind Controlled Trial, Renal Failure,Vol. 28(1),PP.1-5,2006.

[29] P.Susantitaphong, K.Sewaralthahab, E.M. Balk, B. L. Jaber, Vol.17(1),1-58,2013.

[30] N. E.Madia. Short- and Long-Term Effects of Alkali Therapy in Chronic Kidney Disease: A Systematic Review Am J Nephrol , Vol. 35(6) ,PP.540–547,2012.